Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions

Catheterization and Cardiovascular Interventions

Volumn 68, Issue 3, 2006, Pages 352-356

  Kao, John ^a   Lincoff, A Michael ^b   Topol, Eric J ^b   Madrid, Antonio ^c   Price, Matthew J ^d   Sawhney, Neil ^d   Teirstein, Paul S ^d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c St Francis Hospital   (United States)

^d SCRIPPS CLINIC   (United States)

Author keywords

CABG; Direct thrombin inhibitor; GP IIb IIIa; PCI

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; THROMBIN INHIBITOR;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; SAPHENOUS VEIN GRAFT; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ANTITHROMBINS; COMBINED MODALITY THERAPY; CORONARY ARTERY BYPASS; CORONARY DISEASE; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HIRUDINS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THROMBIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 33748307430     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.20735     Document Type: Article

References (12)

1. Roffi M, Mukherjee D, Chew D, et al. Lack of benefit from intravenous platelet glycoprotein Ilb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: A pooled analysis of five randomized clinical trials. Circulation 2002;106:3063-3067.
2. Labinaz M, Kilaru R, Pieper K, et al. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: Results from the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 2002;105:322-327.
3. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002;105:1285-1290.
4. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000;101:570-580.
5. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention REPLACE-2 randomized trial. JAMA 2003;289:853-863.
6. Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004;93:1092-1096.
7. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105:656-662.
8. Kereiakes DJ. Platelet glycoprotein IIb/IIIa inhibition and atheroembolism during bypass graft angioplasty: A cup half full. Circulation 2002;106:2994-2996.
9. Aggrawarl A, Sobel BE, Schneider DJ. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: Implications for coronary intervention. J Thromb Thrombolysis 2002;13:161-165.
10. Mascelli MA, Kleiman NS, Marciniak SJ Jr, et al. Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. Am Heart J 2000;139:696-703.
11. Stone GW, Rogers C, Hermiller J, et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 2003;108:548-553.
12. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs. heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703.